热门资讯> 正文
由于会计错误迫使重报，Ocugen下滑
2024-04-02 23:19
- Ocugen (NASDAQ:OCGN) shares fell sharply on Tuesday after the gene therapy developer, with its 2023 financials, announced its plans to restate certain financials in reaction to several accounting errors.
- The Malvern, Pennsylvania-based biotech said it will restate its consolidated financial statements for the year ending Dec. 31, 2022, with its 2023 10-K filing. The company added that its latest 10-K filing will include restated financials for each of the first three quarters of 2023 and 2022.
- The decision comes after errors in non-cash accounting related to one of OCGN's collaboration arrangements for each restated period.
- However, the errors are not expected to change its cash position, cash runway, or financial projections, Ocugen (OCGN) added, as it reported $39.5M in cash, cash equivalents, and investments indicating a cash runway until Q4 2024.
More on Ocugen
- Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues
- Ocugen shares make gains after US court dismisses class action lawsuits
- Ocugen hits a 52-week high after decision to lower quorum requirement
- Seeking Alpha’s Quant Rating on Ocugen
- Historical earnings data for Ocugen
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
